Methods, compositions, and kits for enhancing female sexual desire and responsiveness
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/19
A61K-031/557
출원번호
US-0880188
(2001-06-12)
발명자
/ 주소
Neal, Gary W.
출원인 / 주소
Vivus, Inc.
대리인 / 주소
Reed, Dianne E.Reed & Eberle LLP
인용정보
피인용 횟수 :
13인용 특허 :
20
초록
Topical application of a prostaglandin directly to the clitoris is effective for enhancing female sexual desire and responsiveness.
대표청구항▼
1. A method for enhancing female sexual desire and response, comprising topically administering to the clitoris of a subject a pharmaceutical composition containing an effective amount of a prostaglandin on an as-needed basis without regular dosing in the context of a chronic dosage regimen. 2. The
1. A method for enhancing female sexual desire and response, comprising topically administering to the clitoris of a subject a pharmaceutical composition containing an effective amount of a prostaglandin on an as-needed basis without regular dosing in the context of a chronic dosage regimen. 2. The method of claim 1, wherein said prostaglandin is selected from the group consisting of prostaglandin E-1; prostaglandin E-2; prostaglandin F-2α; prostaglandin A-1; prostaglandin B-1; prostaglandin D-2; prostaglandin E-M; prostaglandin F-M; prostaglandin H-2; prostaglandin I-2; 19-hydroxy-prostaglandin A-1; 19-hydroxy-prostaglandin B-1; prostaglandin A-2; prostaglandin B-2; 19-hydroxy-prostaglandin A-2; 19-hydroxy-prostaglandin B-2; prostaglandin B-3; prostaglandin F-1α; 15-methyl-prostaglandin F-2α.; 16,16-dimethyl-α-Δ2-prostaglandin E-1 methyl ester; 15-deoxy-16-hydroxy -16-methyl-prostaglandin E-1 methyl ester; 16,16-dimethyl-prostaglandin E-2; 11-deoxy-15-methyl-prostaglandin E-1; 16-methyl-18,18,19,19-tetrahydrocarbacyclin; (16RS)-15-deoxy-16-hydroxy-16-methyl-prostaglandin E-1 methyl ester; (+)-4,5-didehydro -16-phenoxy-α-tetranor-prostaglandin E-2 methyl ester; 11-deoxy-11a ,16,16-trimethyl -prostaglandin E-2; (+)-11a,16a,b-dihydroxy-1,9-dioxo-1-(hydroxymethyl)-16-methyl -trans-prostene; 9-chloro-16,16-dimethyl-prostaglandin E-2; and arboprostil. 3. The method of claim 1, wherein said prostaglandin is selected from the group consisting of prostaglandin E-1, prostaglandin E-2, prostaglandin F-2α, prostaglandin D-2, prostaglandin F-1α, 15-methyl-prostaglandin F-2α, prostaglandin E-3, prostaglandin D-1, and misoprostol. 4. The method of claim 1, wherein said prostaglandin is applied to said clitoris in an amount of 0.1 nanograms to 2,000 μg. 5. The method of claim 1, wherein said prostaglandin is prostaglandin E-1. 6. The method of claim 1, wherein said prostaglandin is prostaglandin E-2. 7. The method of claim 1, further comprising coadministration of at least one coagent selected from the group consisting of agents which inhibit 15-hydroxyprostaglandindehydrogenase, ACE inhibitors, nitro vasodilators, alpha blockers, yohimbine, labetalol, carvedilol, bucindolol, phosphodiesterase inhibitors, muscarinic agents, dopaminergic agonists, ergot alkaloids, opiate antagonists, and polypeptide neurotransmitters. 8. The method of claim 1, wherein the prostaglandin is a unit dose. 9. The method of claim 8, wherein the unit dose is in the range of about 20 nanograms to about 2000 μg. 10. The method of claim 9, wherein the unit dose is in the range of about 200 nanograms to about 500 μg. 11. The method of claim 1, wherein the pharmaceutical composition further comprises a topical carrier that provides release of the prostaglandin from the composition within about 1 minute to about 60 minutes following administration. 12. The method of claim 11, wherein the carrier provides release of the prostaglandin from the composition within about 5 minutes to about 30 minutes following administration. 13. The method of claim 7, wherein the at least one coagent is administered with the prostaglandin. 14. The method of claim 7, wherein the at least one coagent is administered prior to administration of the prostaglandin. 15. The method of claim 7, wherein the at least one coagent is an agent which inhibits 15-hydroxyprostaglandindehydrogenase.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (20)
Nelson ; Norman A., 15-Methyl- and 16-phenoxy-PGF.sub.2 .alpha., amides.
Skuballa Werner (Berlin DEX) Raduechel Bernd (Berlin DEX) Schwarz Norbert (Berlin DEX) Vorbrueggen Helmut (Berlin DEX) Elger Walter (Berlin DEX) Loge Olaf (Berlin DEX) Town Michael-Harold (Berlin DEX, 9-Fluoroprostaglandin derivatives, and use as medicinal agents.
Place Virgil A. (Kawaihae HI) Gale Robert M. (Los Altos CA) Berggren Randall G. (Livermore CA), Dosage and inserter for treatment of erectile dysfunction.
Gioco Diane-Marie (West Haven CT) Zorgniotti ; deceased Adrian (late of Wyland MA by Flavia Zorgniotti ; executrix ), Methods for modulating the human sexual response.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.